down arrow

Cassava Sciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US14817C1071
USD
3.32
0.43 (14.88%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.063.35

52 Week

1.154.97
Valuation
Technical
Day's Volume

CASH

1.1 M

Shareholding (Mar 2025)

FII

5.13%

Held by 67 FIIs

DII

80.48%

Held by 16 DIIs

Promoter

0.00%

How big is Cassava Sciences, Inc.?

22-Jun-2025

As of Jun 18, Cassava Sciences, Inc. has a market capitalization of 100.00 million, with recent quarterly net sales of 0.00 million and a net profit of -72.78 million. As of December 2024, the company reported shareholder's funds of 145.70 million and total assets of 157.53 million.

Market Cap: As of Jun 18, Cassava Sciences, Inc. has a market capitalization of 100.00 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -72.78 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 145.70 million and total assets of 157.53 million.

Read More

What does Cassava Sciences, Inc. do?

22-Jun-2025

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s. It has a market cap of $100 million and reported a net profit loss of $23 million as of March 2025.

Overview:<BR>Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nervous system disorders, specifically targeting neurodegenerative diseases such as Alzheimer’s. It operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 100.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.92 <BR>Return on Equity: -113.49% <BR>Price to Book: 0.78 <BR><BR>Contact Details:<BR>Address: 7801 N Capital of Texas Hwy Ste 260, AUSTIN TX: 78731-1192 <BR>Tel: 1 512 5012444 <BR>Website: https://www.cassavasciences.com/company

Read More

Who are in the management team of Cassava Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Cassava Sciences, Inc. includes Mr. Remi Barbier as Chairman, President, and CEO, and Dr. Nadav Friedmann as Chief Medical and Operating Officer. The Board of Directors also features independent members such as Dr. Robert Gussin and Mr. Michael O'Donnell.

As of March 2022, the management team of Cassava Sciences, Inc. includes:<BR><BR>- Mr. Remi Barbier, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. Nadav Friedmann, who holds the position of Chief Medical and Operating Officer and is also a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Dr. Robert Gussin, Mr. Michael O'Donnell, Mr. Sanford Robertson, and Dr. Patrick Scannon.

Read More

Is Cassava Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of July 28, 2025, Cassava Sciences, Inc. shows a mildly bearish trend with mixed signals from moving averages and MACD, and has significantly underperformed the S&P 500 with a 1-year return of -92.45%.

As of 28 July 2025, the technical trend for Cassava Sciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD shows a mildly bullish signal. The RSI on a monthly basis is bullish, but overall, the mixed signals suggest caution. The stock has significantly underperformed against the S&P 500 over multiple periods, with a 1-year return of -92.45% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 103 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.28

stock-summary
Return on Equity

-141.26%

stock-summary
Price to Book

1.18

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-44 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
50.23%
0%
50.23%
6 Months
53.7%
0%
53.7%
1 Year
-0.9%
0%
-0.9%
2 Years
-84.04%
0%
-84.04%
3 Years
-90.73%
0%
-90.73%
4 Years
-92.76%
0%
-92.76%
5 Years
-55.67%
0%
-55.67%

Cassava Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cassava Sciences, Inc. technically bullish or bearish?

As of 28 July 2025, the technical trend for Cassava Sciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD shows a mildly bullish signal. The RSI on a monthly basis is bullish, but overall, the mixed signals suggest caution. The stock has significantly underperformed against the S&P 500 over multiple periods, with a 1-year return of -92.45% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-261.81%
EBIT to Interest (avg)
-80.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.20%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.83
EV to EBIT
0.08
EV to EBITDA
0.08
EV to Capital Employed
-1.12
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-113.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (14.39%)

Foreign Institutions

Held by 67 Foreign Institutions (5.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -812.90% vs 123.48% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.20",
          "val2": "-66.90",
          "chgp": "32.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "70.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.20",
          "val2": "6.20",
          "chgp": "-812.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 75.00% vs -27.56% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-150.20",
          "val2": "-104.40",
          "chgp": "-43.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "118.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.30",
          "val2": "-97.20",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-45.20
-66.90
32.44%
Interest
0.00
0.00
Exceptional Items
0.00
70.90
-100.00%
Consolidate Net Profit
-44.20
6.20
-812.90%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -812.90% vs 123.48% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-150.20
-104.40
-43.87%
Interest
0.00
0.00
Exceptional Items
118.10
0.00
Consolidate Net Profit
-24.30
-97.20
75.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 75.00% vs -27.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cassava Sciences, Inc. stock-summary
stock-summary
Cassava Sciences, Inc.
Pharmaceuticals & Biotechnology
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
Company Coordinates stock-summary
Company Details
7801 N Capital of Texas Hwy Ste 260 , AUSTIN TX : 78731-1192
stock-summary
Tel: 1 512 5012444
stock-summary
https://www.cassavasciences.com/company
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."